JAK2-Positive Myeloproliferative Neoplasm Presenting as Early Satiety and Post-Prandial Abdominal Pain (ACG 2026) - Aug 29, 2026 - Abstract #P4494; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "Histologic distinction between ET with fibrotic progression and overt myelofibrosis carries meaningful prognostic and therapeutic implications. This case underscores the utility of JAK1/2 inhibition with ruxolitinib for symptom control and splenic volume reduction in JAK2-positive MPN, and the importance of including MPNs in the differential diagnosis of unexplained GI symptoms with splenomegaly."
Cardiovascular • Essential Thrombocythemia • Fibrosis • Hematological Disorders • Hypertension • Immunology • Myelofibrosis • Myeloproliferative Neoplasm • Pain • Polycythemia Vera • Psoriasis • Thrombocytosis • CALR • JAK1 • JAK2
|
|
Zain Qureshi MD 1; Kushagra Gupta MD 2; Sabri Elmounsari MD 1; Sadia Usmani MD 3; Roop Gupta MD 1
|